The effect of inhibitor of angiotensin-converting enzyme on uric acid metabolism

The effect of captopril, i. e. ACI for renal handling of uric acid was studied. How ever, no significant changes were noted in the blood pressure, serum uric acid (SUA), creatinine, Na and Cl levels when captopril in a single dose of 75 mg was orally administered to 10 healthy male adults. On the other hand, a significant rise was recognized in Ccr, CUA, UUAV and UNaV and UcjV levels after captopril administration. An appreciable rise was also noted in the UUA/Ccr and CUA/Ccr levels at their peaks 3-6 hours after administration. Captopril in a daily dose of 37.5 mg was orally administered to 15 patients with essential hypertension and gout for a period of 12 weeks. Captopril alone was given to 8 of these patients (a group given captopril alone) and captopril combined with other antihypertensive drugs were given to 7 (a combined group). As a result, a significant decrease of the blood pressure was noted in both groups in the 4th week of administration, and this therapeutic effect lasted for 12 weeks. Although the SUA level showed a significant decrease in the 4th week in the group given captopril alone, and this effect lasted for 8 weeks. It tended to increase, on the contrary, in the comobined group for 12 weeks. The Ccr, CUA and UUAV levels showed an increase in the group given captopril alone, which tended, however, to decrease in the combined group. Nonetheless, the UUAV/Ccr and CUA/Ccr levels increased in both groups while being given the above dose. Particularly, a significant rise was noted in the UUAV/Ccr level in the group given captopril alone.